Involvement of epimutations in meningioma
- 1 May 2015
- journal article
- review article
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 32 (3) , 163-168
Abstract
Epimutations are heritable and reversible cell markers, which can influence cell function going beyond the effects of DNA mutations. They result from multiple and coordinated mechanisms able to modulate gene expression. Regarding the significance of epigenetics in meningioma, few and somehow contradictory results are available, although promising information has been obtained. Here we highlight the most recent advances about the impact of DNA methylation, histone modifications, and microRNA regulation on meningioma development as well as the interplay between genetic and epigenetic alterations. Data indicate that epigenetics can help to identify novel candidate genes for the management and treatment of meningioma.Keywords
This publication has 59 references indexed in Scilit:
- Epigenetic regulation of p14 and p16 expression in cutaneous and uveal melanomaBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2015
- Epigenetic marks responsible for cadmium-induced melanoma cell overgrowthToxicology in Vitro, 2015
- Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIPInternational Immunopharmacology, 2014
- Identification of microRNA Expression Patterns in Cutaneous and Uveal Melanoma Cell LinesTumori Journal, 2014
- Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanomaBiochemical and Biophysical Research Communications, 2013
- PGE2 inducesinterleukin-8derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylationEpigenetics, 2012
- Class II‐specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL‐8 expression in human melanoma cellsPigment Cell & Melanoma Research, 2012
- Epigenetic Regulation of Gene Expression as an Anticancer Drug TargetCurrent Cancer Drug Targets, 2011
- HDACs class II-selective inhibition alters nuclear receptor-dependent differentiationJournal of Molecular Endocrinology, 2010
- Worms gang up on bacteriaNature Reviews Genetics, 2002